1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

Clinical Infectious Diseases

Volumn 25, Issue 3, 1997, Pages 551-573

  Hughes, Walter T ^a   Armstrong, Donald ^a   Bodey, Gerald P ^a   Brown, Arthur E ^a   Edwards, John E ^a   Feld, Ronald ^a   Pizzo, Philip ^a   Rolston, Kenneth V I ^a   Shenep, Jerry L ^a   Young, Lowell S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; COLONY STIMULATING FACTOR;

ADULT; BACTERIAL INFECTION; CHEMICALLY INDUCED DISORDER; CHILD; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; GRANULOCYTE; HUMAN; NEOPLASM; NEUTROPENIA; PRACTICE GUIDELINE; PYREXIA IDIOPATHICA; REVIEW; TIME; TRANSPLANTATION;

ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CHILD; COLONY-STIMULATING FACTORS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEVER OF UNKNOWN ORIGIN; GRANULOCYTES; HUMANS; NEOPLASMS; NEUTROPENIA; TIME FACTORS;

EID: 0031227964     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513764     Document Type: Article

References (195)

1. Hughes WT, Chairman, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
2. Lawrence RS, Mickalide AD. Preventive services in clinical practice: designing the periodic health examination [editorial]. JAMA 1987; 257:2205-7.
3. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(suppl no. RR-8):l-34.
4. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994; 18:421.
5. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-40.
6. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80(suppl 5c):13-20.
7. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The indentification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-8.
8. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992; 15(suppl 1): S206-15.
9. Dale DC, Guerry D 4th, Wewerka JR, Bull JM, Chusid MJ. Chronic neutropenia. Medicine (Baltimore) 1979;58:128-44.
10. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996; 23:40-46.
11. Whimbey E, Wong B, Kiehn TE, Armstrong D. Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugation in patients with persistent septicemia. J Clin Microbiol 1984; 19:766-71.
12. Flynn PM, Van Hooser B, Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J 1988;7:510-3.
13. Alien U, Smith CR, Prober CG. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child 1986; 140:459-61.
14. Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sei 1984; 287:16-23.
15. Conly JM. Ramotar K, Chubb H, Bow EJ, Louie TJ. Hypoprothrombinemia in febrile, neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984; 150:202-12.
16. Fainstein V, Bodey GP, McCredie KB, et al. Coagulation abnormalities induced by /9-lactam antibiotics in cancer patients. J Infect Dis 1983; 148:745-50.
17. Bochud P-Y, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-64.
18. Press OW, Ramsey PC, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984; 63:189-200.
19. Benezra D, Kiehn TE, Gold JWM, Brown AE, Turnbull ADM, Armstrong D. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med 1988;85:495-8.
20. Raad II, Vartivarian S, Khan A, Bodey GP. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis 1991; 13:1120-5.
21. Blumberg EA, Reboli AC. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996;22:462-6.
22. Kojima A, Shinkai T, Soejima Y, et al. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am J Clin Oncol 1994; 17: 400-4.
23. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98: 224-31.
24. Novâkovà IRQ, Donnelly JP, de Pauw BE. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Ann Hematol 1991;63:195-200.
25. Link H, Maschmeyer G, Meyer P, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 1994;69:231-43.
26. Rubinstein E, Lode H, Grassi C, Antibiotic Study Group. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Clin Infect Dis 1995;20:1217-28.
27. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, Ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115:849-59.
28. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP, the Intercontinental Antimicrobial Study Group. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med 1994; 120:834-44.
29. Hollander NH, Oturai PS, Boas J, et al. Ceftriaxone vs latamoxef in febrile, neutropenic patients with solid tumors receiving cytotoxic chemotherapy. Ann Oncol 1990;l(suppl 2):32.
30. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-7.
31. Malik IA, Aziz Z, Khan WA. A randomized trial to evaluate the role of ofloxacin in the outpatient management of neutropenic febrile patients. Ann Oncol 1992;3(suppl 5): 179.
32. Novâkovà I, Donnelly JP, De Pauw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 1991;35:672-8.
33. Petrilli AS, Melaragno R, Barros KVT, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 1993; 12:916-21.
34. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
35. Petrilli AS, Bianchi A, Kusano E, et al. Fever and granulocytopenia in children with cancer: a study of 299 episodes with two treatment protocols in Brazil. Med Pediatr Oncol 1993;21:356-61.
36. Hauer C, Urban C, Slave I, Gamillscheg A, Lackner H. Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia. Pediatr Hematol Oncol 1990:7:229-41.
37. Yu LC, Shaneyfelt T, Warrier R, Ode D. The efficacy of ticarcillinclavulanate and gentamicin as empiric treatment for febrile neutropenic pédiatrie patients with cancer. Pediatr Hematol Oncol 1994; 11 : 181-7.
38. Novâkovà I, Donnelly P, De Pauw B. Amikacin plus piperacillin versus Ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis 1990;22:705-11.
39. Perkkiö M, Hovi L, Rajantie J, et al. A randomised comparison of Ceftazidime and piperacillin, both in combination with flucloxacillin for treatment of febrile episodes in neutropenic children. Finnish Three-Centre Study. Scand J Infect Dis 1990;22:209-18.
40. Erjavec Z. de Vries-Hospers HG, van Kamp H, van der Waaij D. Halie MR, Daenen SMGJ. Comparison of imipenem versus cefuroxim plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure. Scand J Infect Dis 1994:26:585-95.
41. Samuelsson J, Nilsson P-G. Wahlin A. Lerner R, Winqvist I, Palmblad J. A pilot study of piperacillin and ciprofloxacn. as initial therapy for fever in severely neutropenic leukemia patients. Scand J Infect Dis 1992:24:467-75.
42. Au E, Tow A, Allen DM, Ang PT. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever. Ann Acad Med Singapore 1994; 23: 819-22.
43. Au E, Ang PT. Management of chemotherapy-induced neutropenic sepsis-combination of cephalosporin and aminoglycoside. Ann Acad Med Singapore 1993:22:319-22.
44. Krcméry V Jr.. Koza I, Mardiak J, et al. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients. Chemotherapy 1992:38:74-6.
45. Blanc C, Pollet JP, Bauters F. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases. Chemotherapy 1991:37:382-8.
46. Yataganas X. Rombos Y, Vayopoulos G, Meletis J. Avlami A. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/ amikacin as initial therapy of febrile episodes in neutropenic patients. Chemotherapy 1991:37:376-81.
47. Schmid L, Jeschko M, Wilder-Smith C. et al. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 1991:37:346-52.
48. Studenâ M. Hlavâcovâ E. Hel'pianska L, et al. Teicoplanin plus pefloxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. A randomized study of two once daily regimens in patients with previously inserted catheters. Chemotherapy 1994:40:431-4.
49. Matsui K, Masuda N. Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn .1 Clin Oncol 1991:21:428-34.
50. Urabe A, Takaku F. Mizoguchi H. Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies. Jpn J Med 1991:30:420 3.
51. Preis S. Jürgens H. Friedland C, Oudekotte-David AA. Thomas L. Göbel U. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Padiatr 1993:205:295-9.
52. Oblon D. Ramphai R. A randomized trial of cefepime vs ceftazidime as initial therapy for patients with prolonged fever and neutropenia after intensive chemotherapy [abstract]. Proceedings of the Annual Meeting of the American Association for Cancer Research 1993; 34:A 1362.
53. Gucalp R, Cimino M, Rotstcin C, Carlisle P. Cesari C. Wiernik PH. Cefepime (C) versus piperacillin + gentamicin (P + G) as empirical antibiotic therapy for febrile neutropenic cancer patients [abstract no A1226]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1991:10.
54. Rossini F, Pioltelli P, Mingozzi S. et al. Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. Support Care Cancer 1994:2:259-65.
55. Kieft H, Hoepelman AIM, Rozenberg-Arska M. et al. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemothcr 1994:38:415-21.
56. Cordonnier C. Herbrecht R. Pico JL. et al. Ceiepime'amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997:24: 41-51.
57. Feliu J. Artal A. Gonzalez Baron M. et al. C'omparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob Agents Chemother 1992:36:2816-20.
58. Meunier F. Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991:35:873-8.
59. Rolston KV, Berkey P. Bodey GP. et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992:152:283-91.
60. Smith CL, Milliken S, Powles R, et al. Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients. Br J Haematol 1990;76(suppl2):6-9.
61. Meunier F, van der Auwera P, Aoun M, Bron D. Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia. Br J Haematol 1990:76(suppl 2):49-53.
62. Lim SH, Smith MP. Goldstone AH, Machin SJ. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. Br .1 Haematol 1990;76(suppl 2):41-4.
63. Philpott-Howard JN, Barker K.F, Wade JJ, Kaczmarski RS, Smedley JC. Mufti GJ. Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. J Antimicrob Chemother 1990;26(suppl F):89-99.
64. Johnson PRE. Liu Yin JA. Tooth JA. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemother 1990:26(suppl F):l01-7.
65. Novâkovâ IRO, Donnelly JP. Verhagen CS, de Pauw BE. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother 1990:25:985-93.
66. Kelsey SM. Wood ME, Shaw E, Jenkins GC, Newland AC. A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother 1990:25:149-57.
67. Eggimann P, Glauser MP. Aoun M. Meunier F. Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993:32(suppl B):151-63.
68. Rozdzinski E. Kern WV. Reichle A, et al. Once-daily versus thricedaily dosing of netilmicin in combination with -lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993:31:585-98.
69. Leyland MJ, Bayston KF. Cohen J. et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992:30:843 54.
70. Johnson PRE. Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992:30: 203 14.
71. Bolton-Maggs PUB, van Saene HKF, McDowell HP. Martin J. Clinical evaluation of ticarcillin. with clavulanic acid, and gentamicin in the treatment of febrile episodes in neutropenic children. .1 Antimicrob Chemother 1991:27:669-76.
72. Engcrvall PA. Stiernstedt GT. Günther GC. Björkholm MJ. Triinethoprim-sulfamcthoxazole plus amikacin as first-line therapy and imipenem cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders. J Chemother 1992:4:99 -106.
73. Ziilfikar B. Devecioglu O. Anak S. Ovali F. Gedikoglu G. The efficacy of mezlocillin-amikacin combination in febrile neutropenic children with oncolugic disease. J Chemother 1991:3:250-4.
74. Kelsey SM, Weinhardt B. Pocock CE, Shaw E. Newland AC. Piperacillin; tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. J Chemother 1992:4: 281-5.
75. Santhosh-Kumar CR, Ajarim DSS, Harakati MS, al Momen AK, al Mohareb F. Zeitany RG. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia. J Infect 1992;25:ll-9.
76. Smith L, Will AM, Williams RF, Stevens RF. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990; 20:201-6.
77. Bizette GA, Brooks BJ Jr. Alvarez S. Ceftazidime as monotherapy for fever and neutropenia: experience in a community hospital. J La State Med Soc 1994; 146:448-52.
78. Leoni F, Ciolli S, Pascarella A, Fanci R, Caporale R, Rossi Ferrini P. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993;39:147-52.
79. Miller JA, Butler T, Beveridge RA, et al. Efficacy and tolerability of imipenem-cilastatin versus Ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. ClinTher 1993; 15:486-99.
80. Kattan J, Droz J-P, Ribrag V, Azab M, Boutan-Laroze A, Andremont A. Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. Eur J Cancer 1992;28A:867-70.
81. Oturai PS, Holländer NH, Hansen OP, et al. Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Eur J Cancer 1993;29A:1274-9.
82. Sampi K, Hattori M. Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study [in Japanese]. Gan To Kagaku Ryoho 1992; 19:1315-20.
83. Martino P, Girmenia C, Raccah R, Micozzi A, Cimino G, Mandelli F. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients. Haematologica 1990;75: 69-74.
84. Todeschini G, Veneri D, Carlini S, et al. Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes. Hematol Oncol 1991;9:137-46.
85. Herbrecht R. Damonte JC, Bergerat JP, et al. Piperacillin and netilmicin combination therapy for febrile episodes in neutropenic patients. Infection 1990;18:310-3.
86. Fauser AA, Lang E, Köchling G, Daschner FD. A randomized clinical trial of Ceftriaxone and teicoplanin versus Ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 1994;22:271-5.
87. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus Ceftazidime plus tobramycin in febrile neutropenic children. Infection 1993:21:223-8.
88. Gibson J, Johnson L, Snowdon L, et al. A randomised dosage study of Ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases. Int J Hematol 1994; 60:119-27.
89. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R. Ambulatory treatment with Ceftriaxone in febrile neutropenic children. Isr J Med Sei 1994;30:649-51.
90. Heney D, Lewis IJ, Ghoneim ATM, Chisholm P, Bailey CC. Aztreonam therapy in children with febrile neutropenia: a randomized trial of aztreonam plus flucloxacillin versus piperacillin plus gentamicin. J Antimicrob Chemother 1991;28:117-29.
91. Kelsey SM, Collins PW, Delord C, Weinhard B. Newland AC. A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. Br J Haematol 1990;76(suppl 2):10-3.
92. Charnas R, Luthi AR, Ruch W. Once daily Ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997; 16: 346-53.
93. Micozzi A, Venditti M, Amadori S, Pulsoni A, Tirindelli C, Martino P. Teicoplanin in the treatment of Gram-positive bacteraemia in neutropenic patients. Br J Haematol 1990:76(suppl 2): 19-23.
94. Meunier F, van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991;27(suppl C): 129-39.
95. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995:39:445-52.
96. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13:165-76.
97. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neulropenic patients with cancer. Cancer 1993:71:3640-6.
98. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, Mandelli F. Piperacillin plus amikacin vs. piperacillin plus amikaein plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 1992; 15: 290-4.
99. Kelsey SM. Weinhardt B. Collins PW, Newland AC. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1992:11 : 509-14.
100. Micozzi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993; 12:1 -8.
101. Bodey G, Reuben A, Elting E, et al. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 1991; 10:551-8.
102. Huijgens PC, Ossenkoppele GJ, Weijers TF, et al. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hématologie malignancies. Eur J Haematol 1991:46: 42-6.
103. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996:40:1108-15,
104. Ramphai R, Böiger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992:36:1062-7.
105. Cony-Makhoul P, Brossard G, Marit G, Pellegrin JE. Texier-Maugein J. Reiffers J. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol 1990;76(suppl 2):35-40.
106. Pico JE, Marie JP, Chiche D, et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia'? Results of a randomized trial. Eur J Med 1993;2:275-80.
107. Viscoli C, Moroni C, Boni E, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991:13:397-404.
108. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hématologie malignancies. GIMEMA Infection Program. Antimicrob Agents Chemother 1994:38:2041-6.
109. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163:951 -8.
110. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991; 10:918-23.
111. Bodey GP, Fainstein V, Elting LS, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer 1990; 65:9-16.
112. Kelsey SM, Shaw E, Newland AC. Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therap^ for the treatment of fever in neutropenic patients: a randomised controlled study. J Chemother 1992:4:107-13.
113. Harvey WH, Harvey JH, Moskowitz MJ. Ciprofloxacin/vancomycin (C/ V) as initial empiric therapy in febrile neutropenic leukemia/lymphoma patients (pts) with indwelling venous access devices: preliminary results of an effective regimen with reduced hospital stay [abstract no A1639]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994; 13.
114. Kureishi A, Jewesson PJ, Rubinger M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin Aassociated nephrotoxicity. Antimicrob Agents Chemother 1991;35: 2246-52.
115. Raad II, Whimbey EE, Rolston KVI, et al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996;77:1386-94.
116. Johnson MP, Ramphai R. /J-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162:981-3.
117. Anaissie EJ, Fainstein V, Bodey GP, et al. Randomized trial of betalactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84:581-9.
118. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pédiatrie patients. Infect Dis J 1996; 15:749-57.
119. Ramphai R, Kramer BS, Rand KH. Weiner RS, Shands JW Jr. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother 1983; 12 Suppl A:81-8.
120. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
121. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991; 164:907-16.
122. Klastersky J, Vamecq G, Cappel R, Swings G, Vandenborre L. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum. J Infect Dis 1972; 125:183-6.
123. Sepkowitz KA, Brown AE, Armstrong D. Empirical therapy for febrile, neutropenic patients: persistence of susceptibility of gram-negative bacilli to aminoglycoside antibiotics [letter]. Clin Infect Dis 1994; 19: 810-1.
124. Brown AE, Kiehn TE, Armstrong D. Bacterial resistance in the patient with neoplastic disease. Infect Dis Clin Pract 1995;4(suppl 3): S136-44.
125. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
126. Shenep JL, Hughes WT, Roberson PK, et al. V?ncomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053-8.
127. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14:1201-7.
128. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (H1CPAC). MMWR Morb Mortal Wkly Rep 199S:44(RR-12):1-13.
129. Traub WH, Spohr M, Bauer D. In vitro additive effect of imipenem combined with vancomycin against multiple-drug resistant, coagulasenegative Staphylococci. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 262:361-9.
130. Weisman SJ, Scoopo FJ, Johnson GM, Altman AJ, Quinn JJ. Septicemia in pédiatrie oncology patients: the significance of viridans streptococcal infections. J Clin Oncol 1990;8:453-9.
131. Chow AW, Jewesson PJ, Kureishi A, Phillips GL. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol 1993;51(suppl 54):18-24.
132. Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995;20:907-12.
133. Pizzo PA, Ladisch S, Robichaud K. Treatment of gram-positive septicemia in cancer patients. Cancer 1980:45:206-7.
134. Shenep JL, Flynn PM, Hetherington SV, et al. Continued intravenous antibiotic therapy versus early switch to oral cefixime in neutropenic children with cancer and unexplained fever: a preliminary report [abstract]. In: Program and abstracts of the 32nd Annual Meeting of the Infectious Diseases Society of America (Orlando, FL) 1994:36.
135. Müllen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 1990:8:1998-2004.
136. Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ. Risk factors for recurrent fever after the discontinuation of empiricantibiotic therapy for fever and neutropenia in pédiatrie patients with a malignancy or hématologie condition. J Pediatr 1994; 124:703 -8.
137. Griffin TC, Buchanan GR. Hématologie predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 1992; 121:28-33.
138. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982:72:101-11.
139. Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979:67: 194-200.
140. Hughes WT. Patterson G. Post-sepsis prophylaxis in cancer patients. Cancer 1984;53:137-41.
141. Crane L, Komskian S, Sauber A, et al. Antiobiotic therapy in febrile neutropenic patients; what is the optimum duration of therapy? [abstract no 18]. In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy (Los Angeles). Washington, DC: American Society for Microbiology, 1988.
142. Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984;76:450- 7.
143. Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 1995: 21:1300-2.
144. Bartley DL, Hughes WT, Parvey LS, Parham D. Computed tomography of hepatic and splenic fungal abscesses in leukemic children. Pediatr Infect Dis 1982; 1:317-21.
145. Flynn PM, Shenep JL, Crawford R. Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pédiatrie cancer patients. Cltn Infect Dis 1995;20:964-70.
146. Talbot GH, Provencher M, Cassileth PA. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 1988; 148: 129-35.
147. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NKC, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994;34:226-32.
148. Scherrer R, Geissler K, Kyrie PA, et al. Granulocyte colony-stimuting factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 1993;66:283-9.
149. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:1245-50.
150. Pui C-H, Boyett JM, Hughes WT. Crist WM. A randomized, placebocontrolled trial of recombinant human granulocyte colony-stimulating factor after remission induction therapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781-7.
151. Marina NM, Shema SJ, Bowman LC, et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 1994;23:328-34.
152. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325: 164-70.
153. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1996; 14:1957-60.
154. Riikonen P, Saarinen UM, Mäkipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994; 13:197-202.
155. Anaissie EJ. Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia co//-derived) in cancer patients with fever and neutropenia. Am J Med 1996; 100:17-23.
156. Pon DF, Lim SW, Look RM, et al. Lack of clinically significant fall of white blood cell count (WBC) after early cessation of hematopoietic growth factors for chemotherapy induced neutropenia [abstract no A705]. Proceedings of the Annual Meeting of the Society of Clinical Oncology 1995; 14.
157. Vellenga E, Uyl-de Groot ÇA, de Wit R, et al. Randomized placebocontrolled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy related febrile neutropenia. J Clin Oncol 1996; 14:619-27.
158. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1990;88:36-42.
159. The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hématologie malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991:115:7-12.
160. Liang RHS, Yung RWH, Chan T-K, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 1990;34:215-8.
161. Wimperis JZ, Baglin TP, Marcus RE, Warren RE. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant 1991;8:363-7.
162. Ward TT, Thomas RG, Fye CL, et al. Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebocontrolled Department of Veterans Affairs Cooperative Study. Clin Infect Dis 1993; 17:323-32.
163. Altai M, Schlaifer D, Rubie H, et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. J Clin Oncol 1991;9:865-70.
164. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J ClinOncol 1994; 12:1005-11.
165. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA 1994:272:1183-9.
166. D'Antonio D, lacone A, Fioritoni G, et al. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients. Drugs Exp Clin Res 1992; 18:141 -6.
167. Archimbaud E, Guyotat D, Maupas J, et al. Pefloxacin and vancomycin vs. gentamicin, colistin sulphate and vancomycin for prevention of infections in granulocytopenic patients: a randomised double-blind study. Eur J Cancer 1991;27:174-8.
168. Carlson JW, Fowler JM, Saltzman AK, et al. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecol Oncol 1994:55:415-20.
169. Cortellaro M, Cofrancesco E, Pasargiklian 1. et al. Ciprofloxacin for infection prophylaxis in granulocytopenic patients with acute leukemia. Haematologica 1990; 75:541-5.
170. Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole foe prevention of infection in patients with acute leukemia and granulocytopenia. Infection 1991; 19:73-80.
171. Aming M, Wolf HH, Aul C, Heyll A, Scharf RE, Schneider W. Infection prophylaxis in neutropenic patients with acute leukaemia-a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother 1990;26(suppl D):137-42.
172. D'Antonio D, Piccolomini R, lacone A. et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1994;33:837-44.
173. Fanci R, Leoni F, Bosi A, et al. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. J Chemother 1993;5:119-23.
174. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 1994;40:136-43.
175. Murase T. Chemoprophylaxis of bacterial infections in granulocytopenic patients with new quinolone: a comparison of trimethoprim-sulfamethoxazole (ST) alone with ST plus ciprofloxacin [in Japanese]. Kansenshogaku Zasshi 1995:69:28-32.
176. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
177. Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis 1993; 17(suppl 2):S359-67.
178. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent Chemoprophylaxis for Pneumocyslis carinii pneumonitis. N Engl J Med 1987;316:1627-32.
179. Carratalâ J, Fernândez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.
180. Somolinos N, Arranz R, Del Rey MC, Jiménez ML. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients [letter]. J Antimicrob Chemother 1992:30:730-1.
181. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J. Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681-7.
182. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia [letter]. N Engl J Med 1994;330:1240-1.
183. Goodman JL. Winston DJ. Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing hone marrow transplantation. N Engl J Med 1992;326:845-51.
184. Ellis ME, Clink H. Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994:13:3-11.
185. Wingard JR. Merz WG, Rinaldi MG, Johnson TR. Karp JE. Saral R. Increase in Candida kruxei infection among patients with hone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991:325:1274-7.
186. Schaffner A. Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotcricin B use. and health care costs in patients undergoing intensive chemotherapy for hématologie neoplasias. J Infect Dis 1995:172:1035-41.
187. Bash RO. Katz JA. Cash JV. Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994:74:189 -96.
188. EI-Deiry W. Morris E. High cost of hospital admissions for cancer patients at low risk to develop complications from febrile neutropenia [abstract no A1606]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1993:12.
189. Rolslon KVI. Outpatient management of febrile, neutropenic patients. Infections in Medicine 1995; 12-5.
190. Talcott JA. Whalen A. Clark J, Rieker PP. Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12:107-14.
191. DiNubile MJ. Stopping antibiotic therapy in neutropenic patients. Ann Intern Med 1988; 108:289 92.
192. Lau RC, Doyle JJ. Freedman MH, King SM. Richardson SE. Early discharge of pédiatrie febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 1994; 11 : 417-21.
193. Dranitsaris G, Tran TM. McGeer AJ. et al. Pharmacoeconomics analysis of empiric therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmaeo Economics 1995: 7:49-62.
194. Toner G. Woollen A. Laidlaw C. et al. Eow versus standard dose G-C'SF prophylaxis after chemotherapy: a randomized, crossover comparison [abstract no A1472]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994:13.
195. Centers for Disease Control and Prevention. Assessing the effectiveness of disease and injury prevention programs: costs and consequences. MMWR Morb Mortal Wkly Rep 1995;44(RR-10):1 - 10.